Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 as Adjunctive Therapy in Idiopathic Generalized Epilepsy
NCT06425159Phase 3Terminated
- Sponsor
- Biohaven Ltd.
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in idiopathic generalized epilepsy (IGE) comparing BHV-7000 75 mg with Placebo (2 arms). Primary endpoint: Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure at 24 weeks. Started Jun 2024; status: terminated.
02
Drugs
opakalim
03
Conditions
idiopathic generalized epilepsy (IGE)
Beyond the preview
Go deeper on NCT06425159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425159.